TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $6

Benzinga Newsdesk www.benzinga.com Negative 72.4%

Neg 72.4% Neu 0% Pos 0%

TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $7 to $6.